Shares of the biotech firm rally amid a sharp spike in options activity. Is an FDA ruling coming?
Continued signs of complacency are a concern, but technical support should carry the day and the trade.
Buying VIX calls may prove prohibitively expensive. Selling VIX puts might be an interesting proposition.
AMD continues to outshine Intel, but you wouldn't know it judging from the analysts or put/call activity.
The online retailer is unloved by analysts and heavily shorted; this is a good setup for contrarian buying.
All the 'Dow 11,000' excitement fails to recognize the ongoing woeful performance of big-caps vs. small.
Bankrate and Netflix don't get nearly the attention of the search giant, but their shares have performed at least as well.
With 'everyone' on the big-cap growth bandwagon for 2006, here's the case for small-cap value.
A rocky short-term outlook is overshadowed by bullish long-term prospects for the yellow metal.
Despite the group's standout performance and attractive yields, the Street stays cold. Therein lies opportunity.